高危移植相关血栓性微血管病中依库珠单抗应答模式
该研究纳入85例接受药代/药效学指导依库珠单抗治疗的高危移植相关血栓性微血管病儿童及年轻成人,比较应答者(n=55)与无应答者(n=30)。无应答者全身器官损伤更重、生存更差,需强化给药抑制末端补体活性,且持续蛋白尿及内皮应激和干扰素信号标志物升高。
要点
- 无应答者器官损伤更重且生存显著更差
- 无应答者需强化依库珠单抗给药以抑制sC5b-9
- 持续蛋白尿及ST2、CXCL9升高提示内皮损伤持续
核心结论
- 依库珠单抗无应答者存在持续内皮损伤,可用临床可及生物标志物识别。
- 干扰素信号可能参与治疗抵抗,值得进一步研究。
研究设计与样本
- 研究纳入85例接受药代/药效学指导依库珠单抗治疗的高危TA-TMA儿童和年轻成人。
- 比较应答者(n=55)与无应答者(n=30)的临床和实验室特征。
主要发现
- 无应答者表现为更严重的全身器官损伤和显著更差的生存。
- 药效学分析显示无应答者需强化依库珠单抗给药以抑制末端补体活性(sC5b-9)。
- 实现持久补体控制(持续sC5b-9正常化)所需治疗时间中位35天(IQR 21.5-55)。
- 无应答者尽管sC5b-9持续抑制,仍持续蛋白尿且内皮应激和干扰素信号标志物(ST2、CXCL9)升高。
- 部分接受依库珠单抗联合干扰素-γ阻断剂(emapalumab)的患者补体药效学改善。
关键数值与推荐
- 持久补体控制定义为持续sC5b-9正常化,反映持续补体激活缓解而非药物依赖的短暂抑制。
- sC5b-9是唯一与疾病风险和结局 consistently 相关的临床相关补体生物标志物。
临床怎么用
- 对高危TA-TMA应使用sC5b-9监测补体活性并指导依库珠单抗剂量调整。
- 持续蛋白尿及ST2、CXCL9升高可提示依库珠单抗无应答和持续内皮损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of hematopoietic stem cell transplantation driven by endothelial injury with complement activation and is a leading cause of non-relapse mortality. Terminal complement (C5) blockade with eculizumab improves outcomes in high-risk TA-TMA, yet about one third of patients fail to respond. We studied 85 children and young adults with high-risk TA-TMA treated with pharmacokinetic/pharmacodynamic (PK/PD) guided eculizumab, comparing responders (n=55) and non-responders (n=30). Non-responders exhibited more severe systemic organ injury and markedly inferior survival. PK/PD analysis demonstrated that non-responders required intensified eculizumab dosing to suppress terminal complement activity (sC5b-9). Durable complement control, defined as sustained sC5b-9 normalization reflecting resolution of ongoing complement activation rather than drug-dependent transient suppression, required median 35 days (IQR 21.5-55) of therapy. Non-responders demonstrated persistently elevated proteinuria along with markers of endothelial stress and interferon signaling, including ST2 and CXCL9, despite sustained suppression of sC5b-9 consistent with ongoing endothelial injury not solely explained by circulating terminal complement activity. A subset of patients treated with eculizumab and interferon-γ blocker (emapalumab) demonstrated improved complement pharmacodynamics despite greater baseline complement activation, supporting a pathogenic interaction between interferon signaling and complement-mediated endothelial injury. sC5b-9 remains the only clinically relevant complement biomarker consistently associated with disease risk and outcomes, whereas other quantitative complement component levels did not distinguish responders. Together, these findings indicate that eculizumab non-responders have persistent endothelial injury, identifiable with clinically available biomarkers, and support further investigation of interferon signaling as a potential contributor to treatment resistance.
引用
- Jodele S, Mizuno K, Sabulski A, et al. Patterns of Response to Eculizumab in High-Risk Transplant-Associated Thrombotic Microangiopathy. Blood Adv. 2026. PMID: 42954470. doi:10.1182/bloodadvances.2026020911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。